Clarivate Epidemiology’s coverage of neuromyelitis optica spectrum disorder (NMOSD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of NMOSD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s NMOSD forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NMOSD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate forecasts two NMOSD patient populations:
Literature review (studies included in/excluded from the analyses of neuromyelitis optica spectrum disorder)
Diagnosed prevalent cases
Diagnosed incident cases
Risk / protective factors applied to disease forecast models
Nitin Karakapatla,B.D.S., M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, Mr. Karakapatla was a public health consultant for the Public Health Foundation of India. He holds a master’s degree in public health with biostatistics as a specialization from the Indian Institute of Public Health and a bachelor’s degree in dental surgery from Sri Sai College of Dental Surgery.
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., Manager, Epidemiology. Before joining Clarivate, Mr. Khan worked as a team lead at IKS Health, an organization that works on patient-level healthcare data management. His areas of expertise at the Clarivate epi team are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.